The relationship between CD161 expression and previously published immune-related signatures (Spranger, Bao & Gajewski, 2015; Danilova et al., 2016; Ayers et al., 2017; Hsu et al., 2021), potentially aiding in predicting responses to immunotherapy across different cancers, was analyzed using GSVA. Here, KLRB1 is linked to cancer.